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Abstract
We describe a large series of patients with chronic obstructive pulmonary disease (COPD) and probable invasive pulmonary aspergillo-
sis (IPA), and the risk factors and incidence of the disease in patients with isolation of Aspergillus from lower respiratory tract samples.
From 2000 to 2007, we retrospectively studied all patients admitted with COPD and isolation of Aspergillus (239; 16.3/1000 admissions).
Multivariate logistic regression and survival curves were used. Fifty-three patients had probable IPA (3.6 cases of IPA per 1000 COPD
admissions). IPA affects at least 22.1% of patients with COPD and isolation of Aspergillus in culture. In 33 of the 53 patients with proba-
ble IPA, serum galactomannan was determined; in 14 (42.4%) of these, the result was positive. Five variables were independent predic-
tors of IPA with statistical signiﬁcance: admission to the intensive-care unit, chronic heart failure, antibiotic treatment received in the
3 months prior to admission, the accumulated dosage of corticosteroids equivalent to >700 mg prednisone received in the 3 months
prior to admission, and the similar accumulated dosage of corticosteroids received from admission to the ﬁrst clinical isolation of Asper-
gillus. Multivariate analysis gave an area under the curve of 0.925 (95% CI 0.888–0.962; p <0.001). The overall mean survival of the
cohort was 64.1% (28.3% for IPA patients and 75.2% for non-IPA patients). The median number of days of survival was 48
(95% CI 33.07–62.92). However, we found statistically signiﬁcant differences between patients with IPA (29 days; 95% CI 20.59–37.40)
and patients without IPA (86 days; 95% CI 61.13–110.86) (log rank, p <0.001).
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Introduction
Invasive pulmonary aspergillosis (IPA) affects patients with
neutropenia, solid organ recipients, and those receiving corti-
costeroids and other immunosuppressive therapies [1–13].
Patients with severe chronic obstructive pulmonary disease
(COPD) who are receiving broad-spectrum antibiotics and
corticosteroids are becoming one of the main risk groups
for IPA [14–17]. However, data on this disease are limited,
fragmented, and usually obtained from case reports, or small
collections of cases from different institutions.
Although, in many cases, the isolation of Aspergillus from
lower respiratory tract (LRT) samples (e.g. sputum, bronchial
aspirate, or bronchoalveolar lavage) is the ﬁrst indication of
IPA, the probability of a non-selected risk patient from whom
Aspergillus has been isolated having IPA was calculated to be
12% [7]. Obviously, this probability depends on the underly-
ing condition of the patients: 72% for patients with neutrope-
nia [18,19], 58% for solid organ transplant recipients [18,19],
and 28% for critically ill patients [20]. Unfortunately, the
probability for patients with COPD is almost unknown [21].
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We describe the clinical condition, risk factors and out-
come of a large series of 53 patients with COPD and proba-
ble IPA collected in a single institution.
Materials and Methods
Study period and institutional information
This retrospective study (January 2000 to December 2007)
was carried out in a 1750-bed tertiary hospital in Madrid,
Spain, serving a population that grew from 650 000 to
715 000 inhabitants during the study period. LRT samples
from patients admitted with a diagnosis of COPD were sub-
mitted for microbiological culture when this was clinically
indicated.
IPA is carefully monitored at our hospital, and the usual
practice is to follow up every patient with isolation of Asper-
gillus from clinical samples. During the study period, 100
cases of microbiologically documented probable IPA were
recorded.
The article does not include a statement of patient con-
sent and the approval of internal review boards, because of
its retrospective design.
Microbiology culture and other diagnostic procedures
A total of 429 LRT samples yielded Aspergillus. The distribu-
tion of samples was as follows: sputum, n = 240 (55.9%);
bronchial aspirate, n = 142 (33.1%); bronchoalveolar lavage,
n = 30 (7.0%); and other, n = 17 (4.0%).
All LRT specimens were cultured on conventional media,
including sheep blood agar and chocolate agar. Where
appropriate, LRT samples were further cultured on fungal
media. Cultures were incubated at 32–37C for at least
7 days [22]. Aspergillus isolates were identiﬁed using standard
morphological procedures.
The galactomannan level (Platelia; Bio-Rad, Marnes-la-
Coquette, France) was determined in serum samples upon
request. We used a cut-off of ‡0.5 ng/mL to deﬁne positivity.
Anti-Aspergillus antibodies and precipitins were not measured
in samples from these patients.
Patient inclusion criteria and data collected
The individual charts of patients with a discharge diagnosis of
COPD and isolation of Aspergillus in LRT samples were iden-
tiﬁed and reviewed, and the following variables were
recorded: Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) classiﬁcation for COPD patients [23]; McCabe
and Charlson scores; chronic heart and renal insufﬁciency;
intensive-care unit (ICU) admission; corticosteroid consump-
tion (accumulated dosage of >700 mg of prednisone or
equivalent within the 3 months before admission, and from
admission to the ﬁrst isolation of Aspergillus—a cumulative
dosage that has already been associated with an increased
risk of infection [9]); use of broad-spectrum antibiotics and
antifungal agents; analytical data; imaging data; serum galacto-
mannan level; and antifungal treatment.
Deﬁnition of IPA
Patients were classiﬁed according to the Bulpa criteria [9].
Proven cases required histopathological conﬁrmation. Proba-
ble cases required host factors (patient with COPD usually
treated with corticosteroids, GOLD stage III or IV, with a
recent exacerbation of the dyspnoea and suggestive radiolog-
ical ﬁndings) and microbiological factors (isolation of Aspergil-
lus in LRT samples, or two consecutive serum galactomannan
determinations). Possible cases required host factors but
without Aspergillus isolation or serology. Colonization was
deﬁned as an asymptomatic isolation of Aspergillus in LRT
samples. As only patients with positive cultures were
included, by deﬁnition no possible cases were recorded.
Unfortunately, it was not possible to perform histological
analysis, and no proven cases were demonstrated. Patients
were classiﬁed as having IPA (probable cases) or Aspergillus
colonization.
Number of cases of the disease and distribution of cases
over time
We calculated the number of patients with COPD and clini-
cal isolation of Aspergillus (with or without IPA), the number
of cases of IPA both from overall 1000 hospital admissions
and from COPD patient admissions.
Data analysis and risk factors for IPA in patients with
COPD and clinical isolation of Aspergillus
Categorical variables of patients with and without IPA were
described and compared using the chi-square or Fisher exact
tests; continuous variables were compared using the t-test
and the Mann–Whitney U-test.
Multivariate logistic regression analysis (SPSS, version 14)
was used to study independent variables predictive of IPA.
Survival curves for the overall population and for the groups
of patients with and without IPA at day 120 after admission
were obtained by the Kaplan–Meier method.
Results
Number of patients with Aspergillus isolation and IPA
The hospital had 483 176 admissions, of which 14 618 had
COPD. The mean number of admissions with COPD per
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year (1827) remained stable. Of these, 239 had isolates of
Aspergillus from the LRT samples (0.49 patients with COPD
per 1000 hospital admissions and 16.3 per 1000 COPD
admissions).
Only 53 (22.1%) of them had probable IPA (3.6 cases of
IPA per 1000 COPD admissions). In recent years, we have
detected an increase in the number of cases of IPA in
COPD patients (seven per 1000 admissions in 2000 to 13
per 1000 admissions in 2007) (Fig. 1). COPD was the most
common predisposing condition for the development
of IPA in our hospital, representing 53% of all episodes
investigated.
Microbiological and diagnostic procedures
In 33 of the 53 patients with probable IPA, the serum
galactomannan level was determined; in 14 (42.4%) of
these, the result was positive. We observed false-positive
galactomannan results in two patients: one was receiving
piperacillin–tazobactam (0.7 ng/mL) and the other was
receiving ceftriaxone and parenteral nutrition (0.709 ng/mL)
at the time of serum sampling. The overall mean number of
positive samples with isolation of Aspergillus was 1.8 per
patient. Overall, Aspergillus fumigatus was involved in 83% of
cases of IPA.
Characteristics of the patients evaluated
According to the GOLD criteria for severity of COPD, 32
of the 53 patients with IPA (60.3%) had stage III disease and
21 (39.7%) had stage IV disease.
The demographic and clinical data of patients with COPD
with and without IPA are shown in Table 1. Of the 239
patients evaluated, 176 (73.6%) were admitted because of
exacerbation of COPD; 45 (84.9% of the patients with IPA)
were classiﬁed as probably having IPA. Patients with IPA had
worse clinical conditions than those without IPA. However,
patients with IPA presented non-speciﬁc clinical signs that
are common in exacerbation episodes: COPD-like dyspnoea
(50; 94.3%), fever >38C (18; 33.9%), haemoptysis (ﬁve;
9.4%), and chest pain (nine; 16.9%). In 107 of the 239
patients (44.7%), residual lung lesions were present: 26
(24.2%) had IPA, one had (1%) allergic bronchopulmonary
aspergillosis, and six (5.6%) had aspergilloma, which pro-
gressed to IPA in three cases.
At the time of the isolation of Aspergillus, the infection-
speciﬁc chest radiography ﬁndings were as follows: 107
(44.7%) inﬁltrates, 31 (12.9%) consolidations, 24 (10.4%) nod-
ules, and 11 (4.6%) cavitations; in the remaining patients,
non-speciﬁc ﬁndings were observed (Table 1). The most fre-
quent radiography ﬁndings in patients with COPD and IPA
were bilateral inﬁltrates (29 patients; 54.7%). Worsening
radiological ﬁndings during admission were observed in 66%
of the 53 patients with IPA, as compared with 6.4% of the
patients without IPA (p <0.0001). Thirteen (24.5%) patients
with probable IPA had a computed tomography (CT) scan,
and only three of them showed halo signs; nodules and bilat-
eral inﬁltration were the most common ﬁndings in the
patients evaluated (Table 1). The laboratory results revealed
an elevated white blood cell count (>12 000 cells/mL) in 31
of 53 patients with IPA. Other parameters, such as lactate
dehydrogenase level, also increased in 12 patients with IPA.
Anaemia (haemoglobin <12 g/dL), thrombocytopenia
(<120 000 platelets/mm3) and decrease in total protein
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FIG. 1. Number of cases and trend of
invasive pulmonary aspergillosis (IPA)
episodes. Admissions and number of
patients with chronic obstructive pulmo-
nary disease (COPD) with clinical isola-
tion of Aspergillus during each year of
the study period.
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(<6 g/L) were frequently observed in the later stages of IPA
(Table 2).
In 23 (43.3%) of the 53 patients with probable IPA,
another pathogen (such as Nocardia, methicillin-resistant
Staphylococcus aureus, Pseudomonas, Stenotrophomonas
maltophilia, Enterobacteriaceae) was isolated in at least one
LRT sample. All patients were receiving correct broad-spec-
trum antibiotic therapy, but with a poor clinical response.
At admission, 49 (92.4%) patients with IPA and 105
(56.4%) without IPA were taking corticosteroids. During
admission, corticosteroids were given to 98.1% of patients
with IPA and to 83.3%% of patients without IPA. An accumu-
lated corticosteroid dose >700 mg of prednisone or equiva-
lent during admission was achieved in 41 (77.3%) of the
patients with IPA and in 46 (24.7%) of those without
(p <0.001) (Table 1). Before admission, 97 of the 239
patients received inhaled corticosteroids, and 27 (27.8%) of
them developed IPA. During admission, 119 patients received
inhaled corticosteroids, and 43 (36.1%) developed IPA. The
exact doses received were not available in the medical his-
TABLE 1. Summary of clinical and demographic features of the 239 patients with chronic obstructive pulmonary disease
(COPD) and clinical isolation of Aspergillus included in the study; both groups of patients (with and without invasive pulmonary
aspergillosis (IPA)) were compared
Characteristics IPA Non-IPA patients Overall p
Total, n (%) 53 (22.2) 186 (77.8) 239
Male 43 (81.1) 149 (80.1) 192 (80.3)
Female 10 (18.8) 37 (19.8) 47 (19.6)
Mean age (years)a 69.97 68.24 68.62
Days of admissiona 38.87 29.91 31.90
ICU admission, n (%)b 30 (56.6) 51 (27.4) 81 (33.8) <0.001
Admission by COPD exacerbation, n (%) 45 (84.9) 131 (70.4) 176 (73.6) 0.035
GOLD stage, n (%)
I 0 5 (2.6) 5 (2.1) <0.001
II 0 60 (32.2) 60 (25.1)
III 32 (60.3) 101 (54.3) 133 (55.6)
IV 21 (39.6) 20 (10.7) 41 (17.1)
McCabe score 2–3 2–3 2–3 0.053
Charlson score 3.21 3.26 3.20 0.036
Residual lesions, n (%) 26 (49) 81 (43.5) 107 (44.7) 0.532
Diabetes mellitus, n (%) 12 (22.6) 34 (18.2) 46 (19.2) 0.554
Chronic renal insufﬁciency, n (%)c 6 (11.3) 10 (5.3) 16 (6.6) 0.130
Chronic heart insufﬁciency, n (%) 28 (52.8) 49 (26.3) 77 (32.2) 0.001
Corticosteroid consumption before admission, n (%)d 49 (92.4) 105 (56.4) 154 (64.4) <0.001
<20 mg/day 26 (49.0) 94 (50.5) 120 (50.2)
‡20 mg/day 23 (43.4) 11 (5.9) 34 (14.2)
Accumulated corticosteroid dose before admission, n (%)d
<100 mg 1 (2.0) 5 (2.7) 6 (2.5) 0.003
100–700 mg 26 (49.0) 80 (43.0) 106 (44.3)
>700 mg 22 (41.5) 20 (10.7) 42 (17.6)
Broad-spectrum antibiotics before admission, n (%)d 33 (62.2) 54 (29.1) 87 (36.4) <0.001
Accumulated corticosteroid dose during admission, n (%)e 52 (98.1) 155 (83.3) 207 (86.6)
<100 1 (1.9) 4 (2.1) 5 (2.1) <0.001
100–700 10 (18.8) 105 (56.5) 115 (48.1)
>700 41 (77.3) 46 (24.7) 87 (36.4)
Fever (>38C) at admission, n (%) 18 (33.9) 58 (31.2) 76 (31.8) 0.868
Exacerbation of dyspnoea during admission, n (%) 50 (94.3) 130 (69.9) 180 (75.3) <0.001
Mechanical ventilation, n (%)f 29 (54.7) 41 (22.1) 70 (29.3) <0.001
Central venous catheter, n (%)f 25 (47.1) 37 (19.8) 62 (25.9) <0.001
Chest radiograph, n (%)f
Speciﬁc images
Consolidation 12 (22.6) 19 (10.21) 31 (12.9) 0.034
Nodules 11 (20.7) 13 (6.9) 24 (10.4) 0.007
Cavitations 9 (16.9) 2 (1.0) 11 (4.6) <0.001
Bilateral inﬁltrates 29 (54.7) 36 (19.3) 65 (27.2) <0.001
Unilateral inﬁltrates 10 (18.8) 25 (13.4) 35 (14.6) 0.378
Worsening radiological ﬁndingsg 35 (66) 12 (6.4) 47 (19.7) <0001
CT Scan, n (%)f 13 (24.5) 38 (20.4) 51 (21.3)
Halo sign 3 (5.7) 0 3 (1.3) 0.013
Nodules 10 (18.8) 14 (7.5) 24 (10.0) 0.030
Inﬁltrates 10 (18.8) 9 (4.8) 19 (7.9) 0.003
Other 7 (13.2) 29 (15.6) 36 (15.0) 0.302
CT, computed tomography; ICU, intensive-care unit.
aArithmetic mean.
bPatients who required admission to the ICU.
cCreatinine >1.5 mg/dL.
dWithin the 3 months before the current admission.
eFrom admission to the ﬁrst clinical isolation of Aspergillus.
fAt the time of the ﬁrst clinical isolation of Aspergillus.
gWorsening radiological ﬁndings during admission. Speciﬁc images of infection may appear or even worsen in comparison with previous chest radiographs.
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tory. Most cases of IPA had only pulmonary involvement, but
two patients also had probable brain invasion, as demon-
strated by suggestive radiological ﬁndings.
Probability of infection and risk factors for IPA in patients
with COPD and clinical isolation of Aspergillus
The overall probability of having IPA in a patient with COPD
and clinical isolation of Aspergillus from the LRT was 22.1%.
However, this probability may be inﬂuenced by the number
of samples studied in patients with higher clinical suspicion of
IPA.
Variables with a p-value <0.1 in the univariate analysis are
shown in Table 1. Of these, ﬁve were included in the multi-
variate model: admission to the ICU, chronic heart failure,
antibiotic treatment received in the 3 months prior to
admission, accumulated doses of corticosteroids (>700 mg)
received in the 3 months prior to admission, and accumu-
lated doses of corticosteroids (>700 mg) received from
admission to the ﬁrst clinical isolation of Aspergillus. The mul-
tivariate analysis selected the ﬁve variables with independent
statistical signiﬁcance (Table 3). The model gave an area
under the curve of 0.925 (95% CI 0.888–0.962; chi-square
test, p <0.001).
Antifungal treatment and outcome
Overall, 49 patients survived long enough to receive antifun-
gal therapy (26 monotherapy, and 23 combination therapy
with two or more antifungals). The drugs used were vorico-
nazole (38; 68.4%), itraconazole (nine; 15.7%), amphoteri-
cin B (21; 40.3%), and caspofungin (17; 31.5%). The global
mortality rate was 71.6% (38 patients) (Table 4).
TABLE 2. Summary of analytical ﬁndings of patients with chronic obstructive pulmonary disease and clinical isolation of Asper-
gillus included in the study; both groups of patients (with and without invasive pulmonary aspergillosis (IPA)) were compared
at the time of the ﬁrst isolation of Aspergillus
Analytical parameter
Patients with IPA
n (%)
Patients without IPA
n (%)
pAt admission
At time of the ﬁrst
isolation of Aspergillus At admission
At time of the ﬁrst
isolation of Aspergillus
PaO2 <60 mmHg 34 (64.1) 34 (64.1) 74 (39.7) 65 (34.9) <0.001
PaCO2 >45 mmHg 32 (60.3) 35 (66.0) 65 (34.9) 52 (27.9) <0.001
pH <7.35 or >7.45 31 (58.4) 32 (60.3) 34 (18.2) 26 (13.9) <0.001
HCO3 <23 or >29 mmol/L 28 (52.8) 29 (54.7) 35 (18.8) 34 (18.2) <0.001
SaO2 <90 mmHg 37 (69.8) 35 (66.0) 58 (31.1) 43 (23.1) <0.001
Haemoglobin <12 mg/dL 18 (33.9) 39 (73.5) 35 (18.1) 66 (35.4) <0.001
Haematocrit <35% 18 (33.9) 38 (71.6) 33 (17.7) 61 (32.7) <0.001
Leukocytes >12 000/mL 31 (58.4) 41 (77.3) 84 (45.1) 93 (50.0) <0.001
Platelets <120 000/mm3 5 (9.4) 15 (28.3) 9 (4.8) 10 (5.3) <0.001
Lactate dehydrogenase >460 U/L 12 (22.6) 26 (49.0) 24 (12.9) 25 (13.4) <0.001
Total protein <6 g/dL 14 (26.4) 44 (83.0) 9 (4.8) 49 (26.3) <0.001
Creatinine >1.5 mg/dL 6 (11.3) 8 (15.0) 8 (4.3) 10 (5.3) 0.034
TABLE 3. Variables selected for prediction of invasive pul-
monary aspergillosis by multivariate logistic regression anal-
ysis in patients with chronic obstructive pulmonary disease
and clinical isolation of Aspergillus from lower respiratory
tract (LRT) samples
Wald p OR
95% CI
Inferior Superior
ICU admission 4.758 0.029 2.406 1.093 5.294
Chronic heart failure 3.649 0.056 2.102 0.981 4.504
Accumulated dose of
corticosteroids prior
to admissiona
6.213 0.013 2.987 1.263 7.060
Accumulated dose of
corticosteroids during
admissionb
13.338 0.000 4.568 2.022 10.324
Antibiotic treatmenta 5.924 0.015 2.570 1.202 5.497
Constant 66.327 0.000 0.034
ICU, intensive-care unit.
aIn the 3 months prior to admission.
bFrom admission to the ﬁrst clinical isolation of Aspergillus from LRT samples.
TABLE 4. Outcome of the 239 patients included; survival
was analysed 120 days after admission; differences in sur-
vival are shown for patients with and without invasive pul-
monary aspergillosis (IPA) (p <0.001)
Outcome
Probable IPA
n (%)
Patients without IPA
n (%)
Overall
n (%)
Survival 15 (28.3) 128 (68.8) 143 (59.8)
Death attributable
to Aspergillus
11 (20.7) 0 11 (4.6)
Death attributable
to Aspergillus and
to other causes
26 (49.0) 3 (1.6) 29 (12.1)
Death not attributable
to Aspergillus
1 (1.9) 44 (23.6) 45 (18.8)
Not evaluablea 0 11 (5.9) 11 (4.6)
aThese patients could not be evaluated because they were outpatients or the
clinical chart was not available.
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We followed up patients from admission to day +120, if
survival allowed this. The overall mean survival rate of the
cohort was 64.1% (28.3% for IPA patients and 75.2% for
non-IPA patients). The median number of days of survival
was 48 (95% CI 33.07–62.92). However, we found statisti-
cally signiﬁcant differences between patients with IPA
(29 days; 95% CI 20.59–37.40) and patients without IPA
(86 days; 95% CI 61.13–110.86) (log rank, p <0.001) (Fig. 2).
Discussion
The most common underlying condition in IPA in our institu-
tion is COPD, and almost one in every four patients with
COPD and isolation of Aspergillus from the LRT had IPA. IPA
is more frequent in patients receiving high cumulative doses
of corticosteroids and in those with imaging evidence of pro-
gressive lung disease after admission. Mortality in patients
with COPD and IPA is higher than in those without IPA, and
remains very high despite administration of effective antifun-
gal therapy.
Although prolonged neutropenia and immunosuppression
associated with solid organ transplantation have been recog-
nized as the most common underlying conditions in patients
with IPA [3,24–28], patients with other underlying conditions
(e.g. COPD) are receiving more and more attention
[11,19,29–31].
Several reports have described COPD as an important
underlying condition for IPA [7,9,10,20,32,33]. COPD as an
underlying condition for IPA may be underdetected or
under-reported, because clinical manifestations of the condi-
tion are non-speciﬁc and because the severity of the underly-
ing condition can mask lung invasion by Aspergillus.
Alternatively, better care of COPD patients may prolong
life-expectancy in cases where corticosteroids and broad-
spectrum antibiotics are administered more liberally [34].
The use of these drugs may play a role in the later coloniza-
tion of the lungs by Aspergillus.
An overview of the cases in our institution (not only of a
single service or unit) shows that COPD was the main pre-
disposing condition for IPA, representing 53% of all cases
occurring during the study period.
An important shortcoming in this population is to be found
in the criteria used for diagnosis. The European Organization
for Research and Treatment of Cancer criteria for IPA were
developed for patients with cancer, but, in the absence of
better data, they have also been widely used for non-cancer
populations [35]. In 2007, Bulpa et al. relied on several case
reports to draw up their deﬁnitions of IPA, speciﬁcally for
patients with COPD and isolation of Aspergillus [9]. According
to these criteria, proven cases require histological evidence
of invasion, and the procedure needed to obtain this is rarely
performed in late-stage COPD patients. In our series, we
were not able to perform lung biopsies or autopsies; there-
fore, all cases were classiﬁed as probable IPA, and this pre-
vented us from ruling out false positives and false negatives.
Nevertheless, it is clear that the clinical outcomes of the pop-
ulations classiﬁed as IPA and non-IPA are different. Although
the clinical manifestations and imaging ﬁndings of patients
with COPD and with IPA are non-speciﬁc, the two conditions
share common features and predisposing factors.
Our study is biased, because we selected only those
patients with isolation of Aspergillus from LRT samples, and
not infected patients without isolation. In the absence of his-
topathological data, we decided to exclude patients without
Aspergillus in the LRT.
Serum galactomannan determinations and CT scans are
not routinely performed in this population. Galactomannan
was detected in only 33 patients with IPA (62.2%) (‡0.5 ng/
mL). These ﬁndings are consistent with other reports
[8,15,36,37]. The value of imaging is high for neutropenic
patients [38], although the use of the CT scan in COPD
patients has not been prospectively evaluated. Of the 14
patients with a CT scan in our series, only three (5.7% of all
patients with IPA) presented halo signs.
In order to minimize the limitations of diagnostic proce-
dures and the overestimation of isolation of Aspergillus in
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patients with COPD, we studied the predictive variables for
IPA in patients with COPD and isolation of Aspergillus in
LRT samples. The analysis showed that, in patients with
COPD and in poor clinical condition (ICU admission and
chronic heart failure) who have received antibiotics and high
accumulated dose of corticosteroids, the isolation of Asper-
gillus in LRT samples should suggest to physicians the per-
formance of a CT scan and the initiation of antifungal
therapy.
Further prospective studies evaluating the outcome of
COPD patients with Aspergillus isolated from the LRT are
required. The impact of early and adequate antifungal therapy
in this population has to be assessed, and high-risk patients
should be selected for preventive or early therapy.
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